调控Ang/Tie信号通路治疗眼底新生血管性疾病的研究进展  

Research progress on regulation of Ang/Tie signaling pathway in the treatment of ocular neovascular diseases

作　　者：杨婧研(综述) 魏文斌(审校)[1] Yang Jingyan;Wei Wenbin(Beijing Tongren Eye Center,Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment,Beijing Ophthalmology&Visual Sciences Key Lab,Medical Artificial Intelligence Research and Verification Key Laboratory of the Ministry of Industry and Information Technology,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China)

机构地区：[1]首都医科大学附属北京同仁医院、北京同仁眼科中心、眼内肿瘤诊治研究北京市重点实验室、北京市眼科学与视觉科学重点实验室、医学人工智能研究与验证工信部重点实验室,北京100730

出　　处：《中华实验眼科杂志》2024年第5期467-472,共6页Chinese Journal Of Experimental Ophthalmology

基　　金：国家自然科学基金(82220108017、82141128);北京市自然科学基金(7232024);首都卫生发展科研专项(首发2020-1-2052)。

摘　　要：抗血管内皮生长因子(VEGF)治疗应用于眼底新生血管疾病领域以来,在提高视力、稳定疾病病变和在某些情况下逆转疾病方面显示了卓越的效果。但抗VEGF治疗需要频繁玻璃体内注射给药,患者治疗负担重,长期疗效受影响。前期临床研究发现,调控血管生成素(Ang)/含免疫球蛋白样环和上皮生长因子样域酪氨酸激酶(Tie)通路在眼底新生血管疾病的治疗中有较好的效果。目前已发布了3个Ang/Tie通路阻断药物治疗眼底新生血管疾病的临床研究数据,其中靶向VEGF-A和Ang-2的双特异性免疫球蛋白G1抗体faricimab进入了Ⅲ期临床试验并达到终点,faricimab的2种延长治疗间隔(12周和16周)的给药方案均被证实有效。本文基于已发表的研究报告,就调控Ang/Tie通路在眼底新生血管性疾病治疗中的作用及临床应用作一综述,总结分析Ang/Tie通路的作用机制以及未来药物的应用前景。The emergence of anti-vascular endothelial growth factor(VEGF)therapy has reduced the overall incidence of blindness from ocular neovascular disease.However,frequent intravitreal injections of anti-VEGF therapy are required,which places a significant burden to patients and affects long-term benefits.The angiopoietin(Ang)/tyrosine kinase with immunoglobulin-like and endothelial growth factor-like domains(Tie)pathways are identified as potentially therapeutic regulators for ocular neovascular disease,with additional benefits over anti-VEGF-A therapy.For ocular neovascular diseases,three molecules targeting the Ang/Tie pathway have been studied in clinical trials and the data released,in which faricimab,a bispecific immunoglobulin G1 antibody targeting VEGF-A and Ang-2,entered phaseⅢstudies and met primary clinical endpoints,and two dosing regimens with prolonged treatment intervals(12 and 16 weeks)of faricimab showed reliable efficacy.Overall,the regulation of Ang/Tie pathway provides a new treatment option for ocular neovascular diseases,and it is necessary to deeply understand the mechanism of action of the pathway and accumulate more clinical data in the future.

关 键 词：眼底新生血管疾病 抗新生血管生成 Ang/Tie通路 

分 类 号：R77[医药卫生—眼科]